Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 5/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP4 | P49662 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21848246 | 0.81 | TTR (0.39) | CES1TTRCASP3CASP1CASP4 | |
| SCHEMBL6317683 | 0.78 | ALDH1A1 (0.36) | CES1TTRALDH1A1KDM4EHPGD | |
| SCHEMBL6324873 | 0.78 | ALDH1A1 (0.36) | CES1TTRALDH1A1KDM4EHPGD | |
| SCHEMBL754994 | 0.77 | CES1 (0.50) | CES1TTRCASP3ALDH1A1KDM4E | |
| SCHEMBL6318293 | 0.75 | ALDH1A1 (0.38) | TTRCASP3ALDH1A1HPGDCA1 | |
| SCHEMBL6318296 | 0.75 | ALDH1A1 (0.38) | TTRCASP3ALDH1A1HPGDCA1 | |
| SCHEMBL4015718 | 0.74 | ALDH1A1 (0.52) | CES1ALDH1A1 | |
| SCHEMBL19679859 | 0.72 | CHRM5 (0.42) | CES1TTRCASP3ALDH1A1KDM4E | |
| SCHEMBL25327968 | 0.71 | TDP2 (0.47) | CES1TTRCASP3CASP1CASP4 | |
| SCHEMBL15206754 | 0.69 | TTR (0.50) | CES1TTRCASP3CASP1CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| EP-1135123-B1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| US-5192792-A | Isatine derivatives, and their method of use | WARNER-LAMBERT COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| US-5164404-A | HYDRAZONE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 1992-11-17 | — | — | US | disclosed |
| EP-0503349-A1 | Hydrazone derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1992-09-16 | — | — | EP | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CES1 2434/4885TTR 4103/4885CASP3 3446/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CES1 2526/4885TTR 3947/4885CASP3 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.